The treatment of langerhans cell histiocytosis

Histiocytic Disorders of Children and Adults

Volumn , Issue , 2005, Pages 229-253

  Gadner, Helmut ^a   Ladisch, Stephan ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746290192     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545252.013     Document Type: Chapter

References (80)

1. Arceci, R.J. (1998). Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am,12, 339-357.
2. Avery, M.E., McAfee, J.G. and Guild, H.G. (1957). The course and prognosis of reticuloendothe- liosis (eosinophilic granuloma, Schuller-Christian disease and Letterer-Siwe disease); a study of forty cases. Am J Med,22, 636-652.
3. Bernard, F., Thomas, C., Bertrand, Y., et al. (2005). Report of multicenter pilot study of 2-CdA and Ara-C combined chemotherapy in refractory Langerhans cell histiocytosis with hematological dysfunction. Eur J Cancer (in press) (accepted for publication Nov. 2004).
4. Berry, D.H., Gresik, M.V., Humphrey, B., et al. (1986). Natural history of histiocytosis X: a Pediatric Oncology Group Study. Med Pediatr Oncol,14, 1-5.
5. Berry, D.H., Gresik, M., Maybee, D., et al. (1990). Histiocytosis X in bone only. Med Pediatr Oncol,18,292-294.
6. Braier, J., Chantada, G., Rosso, D., et al. (1999). Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol,16, 377-385.
7. Broadbent, V. and Gadner, H. (1998). Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am,12, 327-338.
8. Broadbent, V. and Pritchard, J. (1997). Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol,28, 289-293.
9. Broadbent, V., Gadner, H., Komp, D., et al. (1989a). Histiocytosis syndromes in children II. Approach to the clinical and laboratory evaluation of children with Langerhans-cell histiocytosis. Med Ped Oncol,17,492-495.
10. Broadbent, V., Pritchard, J., Yeomans, E. (1989b). Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X). Med Pediatr Oncol,17, 97-100.
11. Brown, R.E. (2001). Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis? Med Pediatr Oncol,36, 641-643.
12. Ceci, A., Terlizzi, M.D., Colella, R., et al. (1993). Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-HX 83 Study. Med Pediatr Oncol,21, 259-264.
13. Culic, S., Jakobson, A., Culic, V., et al. (2001). Etoposide as the basic and interferon-alpha as the maintenance therapy for Langerhans cell histiocytosis: a RTC. Pediatr Hematol Oncol,18, 291-294.
14. Daneshbod, K. and Kissane, J.M. (1978). Idiopathic differentiated histiocytosis. Am J Clin Pathol,70, 381-389.
15. Donadieu, J., Rolon, M.A., Pion, E.M., et al., for The French LCH Study Group. (2004a). Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab,89, 604-609.
16. Donadieu, J., Rolon, M.A., Thomas, C., et al., for The French LCH Study Group. (2004b). Endocrine involvement in pediatric-onset Langerhans’ cell hisiotcytosis: a population-based study. J Pediatr,144, 344-350.
17. Dunger, D.B., Broadbent, V., Yeoman, E., et al. (1989). The frequency and natural history of diabetes insipidus in children with Langerhans cell histiocytosis. New Engl J Med,321,1157-1162.
18. Egeler, R.M. (2001). More on pamidronate in Langerhans’-cell histiocytosis. New Engl J Med, 345, 1502-1503.
19. Egeler, R.M. and D’Angio, G.J. (1995). Langerhans cell histiocytosis. J Pediatr,127, 1-11.
20. Egeler, R.M., de Kraker, J., Voute, P.A. (1993). Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol,21, 265-270.
21. Egeler, R.M., Neglia, J.P., Arico, M., et al. (1998). The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am,12, 369-378.
22. Egeler, R.M., Thompson, R.C., Voute, P.A., et al. (1992). Intralesional infiltration of corticosteroids in localized Langerhans cell histiocytosis. J Pediatr Orthop,12, 811-814.
23. Farran, R.P., Zaretski, E. and Egeler, R.M. (2001). Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol,23, 54-56.
24. Feldges, A. (1981).Childhood histiocytosis X: clinical aspects and therapeutic approaches. Haematol Blood Transfusion,27,225-228.
25. Gadner, H. and Grois, N. (1993). The histiocytosis syndromes. In: Fitzpatrick, T.B., Eisen, A.Z., Wolff, K., Freedberg, I.M. and Austen, K.F., eds. Dermatology in General Medicine, Vol. II, Mc Graw-Hill, Inc., New York. pp. 2003-2017.
26. Gadner, H., Heitger, A., Grois, N., et al. (1994). Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol,23, 72-80.
27. Gadner, H., Grois, N., Arico, M., et al. (2001). A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr,138, 728-734.
28. Gramatovici, R. and D’Angio, G.J. (1988). Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans’ cell histiocytosis). Med Pediatr Oncol,16, 259-262.
29. Greenberger, J.S., Cassady, J.R., Jaffe, N., et al. (1979). Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int J Radiat Oncol Biol Phys,5, 1749-1755.
30. Greenberger, J.S., Crocker, A.C., Vawter, G., et al. (1981). Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine,60, 311-338.
31. Grois, N., Flucher-Wolfram, B., Heitger, A., et al. (1995). Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med Pediatr Oncol,24, 248-256.
32. Grois, N.G., Favara, B.E., Mostbeck, G.H., et al. (1998). Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am,12, 287-305.
33. Grois, N. and Gadner, H. (2004). Re: Is unifocal Langerhans cell histiocytosis of the orbit a ‘CNS- risk’ lesion? (letter to the editor) Pediatr Blood Cancer,43, 300-301.
34. Hashimoto, K. and Pritzker, M.S. (1973). Electron microscopic study of reticulohistiocytoma. An unusual case of congenital, self-healing reticulohistiocytosis. Arch Dermatol,107, 263-270.
35. Haupt, R., Fears, T.R., Heise, A., et al. (1997). Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans’ cell histiocytosis in Italian and Austrian-German populations. Int J Cancer,71, 9-13.
36. Haupt, R., Nanduri, V., Calevo, M.G., et al. (2004). Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society - Late Effects Study Group. Pediatr Blood Cancer, 42, 438-444.
37. Henter, J.I., Karlen, J., Calming, U., et al. (2001). Successful treatment of Langerhans-cell histiocytosis with etanercept. New Engl J Med,345, 1577-1578.
38. Howell, S.J., Wilton, P. and Shalet, S.M. (1998). Growth hormone replacement in patients with Langerhan’s cell histiocytosis. Arch Dis Child,78, 469-473.
39. Kelly, K.M. and Pritchard, J. (1994). Monoclonal antibody therapy in Langerhans cell histiocytosis - feasible and reasonable? Br J Cancer,70(Suppl XXIII), 54-55.
40. Kilpatrick, S.E., Wenger, D.E., Gilchrist, G.S., et al. (1995). Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer, 76, 2471-2484.
41. Komp, D.M. (1981). Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol,3, 165-168.
42. Komp, D.M., Vietti, T.J., Berry, D.H. et al. (1977). Combination chemotherapy and histiocytosis X. Med Pediatr Oncol,3, 267-273.
43. Komp, D.M., Mahdi, A.E., Starling, K.A., et al. (1980). Quality of survival in histiocytosis X: a Southwest Oncology Group Study. Med Pediatr Oncol,8, 35-40.
44. Ladisch, S. (1983). Histiocytosis. In: Willoughby, M.L.N. and Siegel, S.E., eds. Butterworth’s International Medical Reviews, Pediatrics Hematology, Vol. I, Butterworth Scientific, London, pp. 95-109.
45. Ladisch, S. and Gadner, H. (1994). Treatment of Langerhans cell histiocytosis - evolution and current approaches. Br J Cancer,70,41-46.
46. Ladisch, S. and Jaffe, E. (2002). The histiocytoses. In: Pizzo, P.A. and Poplack, D.G., eds.Principles and Practice of Pediatric Oncology, Lippincott, Philadelphia, pp. 733-750.
47. Ladisch, S., Gadner, H., Arico, M., et al. (1994). LCH-I: a randomised trial of etoposide versus vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol,23, 107-110.
48. Lahey, E. (1975). Histiocytosis X: an analysis of prognostic factors. J Pediatr,87, 184-189.
49. Lahey, M.E. (1962). Prognosis in reticuloendotheliosis in children. JPediatr,60, 664-668.
50. Lahey, M.E., Smith, B. and Heyn, R. (1979). Immunologic studies in histiocytosis X (meeting abstract). Proc Am Ass Cancer Res,20,436.
51. LCH-III. Treatment protocol of the third international study for Langerhans cell histiocytosis (www.histio.org)
52. McClain, K.L., Gonzales, J., Jonkers, R., et al. (2002). Need for a cooperative study: Pulmonary Langerhans cell histocytosis and its management in adults. (Position paper). Med Pediatr Oncol,39, 35-39.
53. McCowage, G.B., Frush, D.P. and Kurtzberg, J. (1996). Successful treatment of two children with Langerhans’ cell histiocytosis with 2'-deoxycoformycin. J Pediatr Hematol Oncol,18, 154-158.
54. McLelland, J., Broadbent, V., Yeomans, E., et al. (1990). Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child,65, 301-303.
55. Minkov, M., Grois, N., Broadbent, V., et al. (1999). Cyclosporine. A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol, 33, 482-485.
56. Minkov, M., Grois, N., Braier, J., et al., for the Histiocyte Society. (2002a). Immunosuppressive treatment for chemotherapy resistant multisystem Langerhans cell histiocytosis. Med Pediatr Oncol,40, 253-256.
57. Minkov, M., Grois, N., Heitger, A., et al. (2002b). Response to initial treatment: an important prognostic predictor in multisystem Langerhans cell histiocytosis. Med Pediatr Oncol,39, 581-585.
58. Misery, L., Larbre, B., Lyonnet, S., et al. (1993). Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol,18,487.
59. Morgan, C. (1994). Myeloablative therapy and bone marrow transplantation for Langerhans cell histiocytosis. Br J Cancer, 70(Suppl XXIII), 52-53.
60. Munn, S. and Chu, A.C. (1998). Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am,12, 269-286.
61. Munn, S.E., Oliver, L., Broadbent, V., et al. (1999). Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol, 32, 247-249.
62. Neumann, G., Kolde, G. and Bonsmann, G. (1988). Histiocytosis X in an elderly patient. Ultrastructure and immunochemistry after PUVA photochemotherapy. Br J Dermat,19, 385-391.
63. Nezelof, C., Frileux-Herbet, F. and Cronier-Sachot, J. (1979). Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer,44, 1824-1838.
64. Oberman, H.A. (1961). Idiopathic histiocytosis. A clinicopathologic study of 40 cases and review of the literature. Pediatrics, 28, 307-327.
65. Selch, M.T. and Parker, R.G. (1990). Radiation therapy in the management of Langerhans cell histiocytosis. Med Pediatr Oncol,18, 97-102.
66. Sheehan, M.P., Atherton, D.J., Broadbent, V., et al. (1991). Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr,119, 317-321.
67. Slater, J.M. and Swarm, O.J. (1980). Eosinophilic granuloma of bone. Med Pediatr Oncol, 8, 151-164.
68. Tazi, A., Soler, P. and Hance, A.J. (2002). Adult pulmonary Langerhans’ cell histiocytosis. Thorax, 55, 405-416.
69. The French Langerhans Cell Histiocytosis Group. (1996). A multicentric retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child, 75, 17-24.
70. Titgemeyer, C., Grois, N., Minkov, M., et al. (2001). Pattern and course of single-system disease in Langerhans cell histiocytosis. Med Pediatr Oncol,37, 1-7.
71. Toogood, I.R., Ellis, W.M. and Ekert, H. (1979). Prognostic criteria, treatment and survival in disseminated histiocytosis X. Aust Paediatr J,15, 91-95.
72. Vassallo, R., Ryu, J.H., Colby, T.V., et al. (2000). Pulmonary Langerhans’-cell histiocytosis. New Engl J Med,342, 1969-1978.
73. Watts, J. and Files, B. (2001). Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol,18, 199-204.
74. Weitzman, S., Wayne, A.S., Arceci, R., et al. (1999). Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the Histiocyte Society and review of the literature. Med Pediatr Oncol,33,476-481.
75. Willis, B., Ablin, A., Weinberg, V., et al. (1996). Disease course and late sequelae of Langerhans cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol, 14,2073-2082.
76. Willman, C., Busque, L., Griffith, B., et al. (1994). Langerhans’ cell histiocytosis (histiocytosis X) - a clonal proliferative disease. New Engl J Med,331, 154-160.
77. Woo, K.I. and Harris, G.J. (2003). Eosinophilic granuloma of the orbit - understanding the paradox of aggressive destruction responsive to minimal intervention. Ophthal Plast Reconstr Surg, 19, 429-439.
78. Womer, R.B., Anunciato, K.R. and Chehrenama, M. (1995). Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol,25, 70-73.
79. Writing Group of the Histiocyte Society. (1987). Histiocytosis syndromes in children. Lancet, 1,208-209.
80. Zeller, B., Storm-Mathisen, I., Smevik, B., et al. (2000). Multisystem Langerhans-cell histiocytosis with life-threatening pulmonary involvement - good response to cyclosporine A. Med Pediatr Oncol, 35, 438-442.